EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines

The first approved COVID‐19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA‐1273 and AstraZeneca recombinant adenoviral ChAdOx1‐S. Soon after approval, severe allergic reactions to the mRNA‐based vaccines that resolved after treatment were reported. Regulatory agencies from the European Unio...

Full description

Saved in:

Bibliographic Details
Published in:	Allergy (Copenhagen) Vol. 76; no. 6; pp. 1629 - 1639
Main Authors:	Sokolowska, Milena, Eiwegger, Thomas, Ollert, Markus, Torres, Maria J., Barber, Domingo, Del Giacco, Stefano, Jutel, Marek, Nadeau, Kari C., Palomares, Oscar, Rabin, Ronald L., Riggioni, Carmen, Vieths, Stefan, Agache, Ioana, Shamji, Mohamed H.
Format:	Journal Article
Language:	English
Published:	Denmark Blackwell Publishing Ltd 01.06.2021 John Wiley and Sons Inc
Subjects:	Allergens Allergies Anaphylaxis COVID COVID-19 COVID-19 vaccines Diagnosis Dosage Eaaci Position Paper Eaaci Position Papers Immunization Immunogenicity Medical diagnosis mRNA Patients Regulatory agencies SARS‐CoV Vaccines virus
ISSN:	0105-4538, 1398-9995, 1398-9995
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!